A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT)

Original language	English
Journal	Therapeutic advances in medical oncology
Volume	14
DOIs	https://doi.org/10.1177/17588359221109196
Publication status	Published - 2022

angiogenesis, biomarkers, esophagogastric cancer, paclitaxel pharmacokinetics, palliative chemotherapy, targeted therapy

ID: 24872629

Generic Portal